A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...

Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

In tandem with September’s Prostate Cancer Awareness Month, Cleveland Diagnostics is kicking off a campaign to boost awareness of and education around screening tests for the disease. The flagship ...